Tonix Pharmaceuticals Holding Corp.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders, immunology, and infectious diseases. The company offers a pipeline of product candidates including TNX-102 SL, a non-opioid sublingual tablet for fibromyalgia and acute stress reaction post-traumatic stress disorder; TNX-1300, an IV formulation of cocaine for rapid-onset cocaine intoxication; TNX-1500, a monoclonal antibody targeting CD40 ligand for organ transplant rejection and autoimmune conditions; TNX-2900, a nasal spray oxytocin antagonist for Prader-Willi syndrome; and TNX-801, a live virus vaccine for smallpox and mpox; along with TNX-1800, a live virus vaccine for SARS-CoV-2. These products target unmet medical needs in pain management, neurology, vaccinology, and biologics, serving patients through clinical development and potential commercialization. Founded in 2007 and headquartered in Chatham, New Jersey, Tonix Pharmaceuticals operates primarily in the United States with clinical trials conducted globally. In recent developments, the company reported positive Phase 3 data for TNX-102 SL in fibromyalgia during 2024, advancing toward an NDA filing expected in early 2025; expanded its infectious disease portfolio through preclinical progress on TNX-801 and TNX-1800 amid mpox outbreaks; and strengthened its balance sheet via a public offering in late 2024, supporting ongoing CNS and immunology programs. Additionally, Tonix entered a strategic collaboration with Makana Therapeutics in 2024 to co-develop TNX-1500 for transplant indications, marking a key alliance in biologics.
Company News
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical Review
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer
Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
Tonix Shares Jump After Landing Second Commercial Payer Agreement For TONMYA
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives